Literature DB >> 6950410

Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

C W Vogel, H J Müller-Eberhard.   

Abstract

The unique specificity of monoclonal antibodies (Ab) was combined with the cell-killing function of the cytolytic alternative pathway of complement. The functionally C3b-like glycoprotein of cobra venom was linked to a murine monoclonal Ab directed to a human melanoma-associated antigen by a disulfide bond, by using a heterobifunctional crosslinking reagent. The covalent monoclonal Ab-cobra venom factor (CVF) complex exhibited specific cytolytic activity in the presence of normal or C4-deficient serum. It induced killing of melanoma cells but not of LG-2 lymphoblastoid cells or P815 mastocytoma cells. The cytolytic action of the monoclonal Ab-CVF complex was selective in that it was limited to the melanoma cells when these were mixed with one of the two other cell lines. In absence of serum, the complex was noncytotoxic. Monoclonal Ab or CVF alone had no cytolytic activity with or without serum. It is concluded that CVF covalently linked to melanoma cell-bound AB forms the stable C3/C5 convertase with factors B and D of the alternative pathway, which in turn causes formation of the membrane attack complex and thereby cell death.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6950410      PMCID: PMC349339          DOI: 10.1073/pnas.78.12.7707

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.

Authors:  A Miyama; T Kato; S Horai; J Yokoo; S Kashiba
Journal:  Biken J       Date:  1975-12

2.  C3 requirements for formation of alternative pathway C5 convertase.

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-08       Impact factor: 5.422

3.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

4.  Alternative pathway for the activation of complement in human serum. Formation and composition of the complex with cobra venom factor that cleaves the third component of complement.

Authors:  W Vogt; L Dieminger; R Lynen; G Schmidt
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1974-02

5.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

6.  Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement).

Authors:  C A Alper; D Balavitch
Journal:  Science       Date:  1976-03-26       Impact factor: 47.728

7.  The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation.

Authors:  P J Lachmann; L Halbwachs
Journal:  Clin Exp Immunol       Date:  1975-07       Impact factor: 4.330

8.  Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Authors:  R G Medicus; O Götze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1976-10-01       Impact factor: 14.307

9.  The membrane attack mechanism of complement. Verification of a stable C5-9 complex in free solution.

Authors:  W P Kolb; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

10.  Modulation of the alternative complement pathways by beta 1 H globulin.

Authors:  K Whaley; S Ruddy
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

View more
  8 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition.

Authors:  D E Martin; F J Chiu; I Gigli; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

Review 3.  The alternative pathway of complement.

Authors:  M K Pangburn; H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

Review 4.  The membrane attack complex.

Authors:  H J Müller-Eberhard
Journal:  Springer Semin Immunopathol       Date:  1984

5.  An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

Authors:  Anna Sergeeva; Gheath Alatrash; Hong He; Kathryn Ruisaard; Sijie Lu; James Wygant; Bradley W McIntyre; Qing Ma; Dan Li; Lisa St John; Karen Clise-Dwyer; Jeffrey J Molldrem
Journal:  Blood       Date:  2011-02-04       Impact factor: 22.113

6.  Molecular cloning and derived primary structure of cobra venom factor.

Authors:  D C Fritzinger; R Bredehorst; C W Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 7.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

8.  The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb.

Authors:  Vengadesan Krishnan; Karthe Ponnuraj; Yuanyuan Xu; Kevin Macon; John E Volanakis; Sthanam V L Narayana
Journal:  Structure       Date:  2009-04-15       Impact factor: 5.006

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.